CA3114528A1 - Systemes et methodes pour le traitement du dysfonctionnement urinaire - Google Patents
Systemes et methodes pour le traitement du dysfonctionnement urinaireInfo
- Publication number
- CA3114528A1 CA3114528A1 CA3114528A CA3114528A CA3114528A1 CA 3114528 A1 CA3114528 A1 CA 3114528A1 CA 3114528 A CA3114528 A CA 3114528A CA 3114528 A CA3114528 A CA 3114528A CA 3114528 A1 CA3114528 A1 CA 3114528A1
- Authority
- CA
- Canada
- Prior art keywords
- stimulation
- nerve
- stimulator
- ipc
- person
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 207
- 238000011282 treatment Methods 0.000 title claims description 226
- 230000004064 dysfunction Effects 0.000 title claims description 11
- 230000002485 urinary effect Effects 0.000 title description 16
- 230000000638 stimulation Effects 0.000 claims abstract description 1188
- 210000005036 nerve Anatomy 0.000 claims abstract description 687
- 210000002972 tibial nerve Anatomy 0.000 claims abstract description 381
- 230000004913 activation Effects 0.000 claims abstract description 88
- 210000003127 knee Anatomy 0.000 claims abstract description 32
- 230000004044 response Effects 0.000 claims description 132
- 230000004936 stimulating effect Effects 0.000 claims description 69
- 230000001154 acute effect Effects 0.000 claims description 63
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 60
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 59
- 208000020629 overactive bladder Diseases 0.000 claims description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 42
- 238000002646 transcutaneous electrical nerve stimulation Methods 0.000 claims description 42
- 210000002683 foot Anatomy 0.000 claims description 37
- 208000035475 disorder Diseases 0.000 claims description 31
- 230000005684 electric field Effects 0.000 claims description 28
- 230000003213 activating effect Effects 0.000 claims description 27
- 210000001699 lower leg Anatomy 0.000 claims description 23
- 210000003205 muscle Anatomy 0.000 claims description 23
- 238000002604 ultrasonography Methods 0.000 claims description 20
- 206010046555 Urinary retention Diseases 0.000 claims description 18
- 210000003141 lower extremity Anatomy 0.000 claims description 15
- 238000011156 evaluation Methods 0.000 claims description 14
- 238000007920 subcutaneous administration Methods 0.000 claims description 12
- 208000035824 paresthesia Diseases 0.000 claims description 11
- 238000003384 imaging method Methods 0.000 claims description 10
- 230000003447 ipsilateral effect Effects 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 5
- 210000003752 saphenous vein Anatomy 0.000 claims description 5
- 206010010774 Constipation Diseases 0.000 claims description 4
- 230000036772 blood pressure Effects 0.000 claims description 4
- 208000034347 Faecal incontinence Diseases 0.000 claims description 3
- 210000002303 tibia Anatomy 0.000 claims description 3
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 2
- 238000002594 fluoroscopy Methods 0.000 claims description 2
- 208000022170 stress incontinence Diseases 0.000 claims description 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 186
- 230000007383 nerve stimulation Effects 0.000 abstract description 112
- 230000001537 neural effect Effects 0.000 abstract description 70
- 230000005284 excitation Effects 0.000 abstract description 36
- 230000003247 decreasing effect Effects 0.000 abstract description 20
- 238000005516 engineering process Methods 0.000 abstract description 15
- 239000000758 substrate Substances 0.000 abstract description 11
- 208000014001 urinary system disease Diseases 0.000 abstract description 4
- 238000012369 In process control Methods 0.000 description 589
- 238000004190 ion pair chromatography Methods 0.000 description 589
- 210000004544 dc2 Anatomy 0.000 description 578
- 210000003932 urinary bladder Anatomy 0.000 description 217
- 230000000694 effects Effects 0.000 description 182
- 210000001519 tissue Anatomy 0.000 description 168
- 238000001994 activation Methods 0.000 description 86
- 230000008901 benefit Effects 0.000 description 68
- 230000001965 increasing effect Effects 0.000 description 68
- 238000012216 screening Methods 0.000 description 68
- 230000001225 therapeutic effect Effects 0.000 description 66
- 206010001497 Agitation Diseases 0.000 description 57
- 230000001976 improved effect Effects 0.000 description 48
- 230000002035 prolonged effect Effects 0.000 description 48
- 230000005764 inhibitory process Effects 0.000 description 47
- 230000007423 decrease Effects 0.000 description 37
- 230000006870 function Effects 0.000 description 35
- 239000007943 implant Substances 0.000 description 35
- 241000700159 Rattus Species 0.000 description 34
- 238000002513 implantation Methods 0.000 description 34
- 230000008859 change Effects 0.000 description 33
- 238000004891 communication Methods 0.000 description 33
- 208000024891 symptom Diseases 0.000 description 33
- 210000000273 spinal nerve root Anatomy 0.000 description 32
- 230000000763 evoking effect Effects 0.000 description 29
- 238000013461 design Methods 0.000 description 28
- 239000000835 fiber Substances 0.000 description 28
- 210000000578 peripheral nerve Anatomy 0.000 description 28
- 238000005094 computer simulation Methods 0.000 description 27
- 208000002193 Pain Diseases 0.000 description 26
- 210000003423 ankle Anatomy 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 25
- 230000037361 pathway Effects 0.000 description 25
- 239000003814 drug Substances 0.000 description 24
- 229940079593 drug Drugs 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- 230000002964 excitative effect Effects 0.000 description 22
- 239000000463 material Substances 0.000 description 22
- 230000036407 pain Effects 0.000 description 22
- 230000002401 inhibitory effect Effects 0.000 description 21
- 210000002414 leg Anatomy 0.000 description 21
- 238000010586 diagram Methods 0.000 description 20
- 230000035807 sensation Effects 0.000 description 20
- 230000008602 contraction Effects 0.000 description 19
- 210000001186 vagus nerve Anatomy 0.000 description 18
- 210000004556 brain Anatomy 0.000 description 17
- 230000004007 neuromodulation Effects 0.000 description 16
- 230000011514 reflex Effects 0.000 description 16
- 230000001953 sensory effect Effects 0.000 description 16
- 239000004020 conductor Substances 0.000 description 15
- 230000002093 peripheral effect Effects 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 238000004088 simulation Methods 0.000 description 15
- 238000002651 drug therapy Methods 0.000 description 13
- 230000003287 optical effect Effects 0.000 description 13
- 238000005259 measurement Methods 0.000 description 12
- 230000002708 enhancing effect Effects 0.000 description 11
- 230000005012 migration Effects 0.000 description 11
- 238000013508 migration Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 230000000007 visual effect Effects 0.000 description 11
- 208000004168 Underactive Urinary Bladder Diseases 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 230000001684 chronic effect Effects 0.000 description 10
- 230000006690 co-activation Effects 0.000 description 10
- 230000001276 controlling effect Effects 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 230000033001 locomotion Effects 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 210000004126 nerve fiber Anatomy 0.000 description 10
- 210000000944 nerve tissue Anatomy 0.000 description 10
- 206010021639 Incontinence Diseases 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 210000001428 peripheral nervous system Anatomy 0.000 description 9
- 210000000278 spinal cord Anatomy 0.000 description 9
- 210000001032 spinal nerve Anatomy 0.000 description 9
- UELITFHSCLAHKR-UHFFFAOYSA-N acibenzolar-S-methyl Chemical compound CSC(=O)C1=CC=CC2=C1SN=N2 UELITFHSCLAHKR-UHFFFAOYSA-N 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 210000003099 femoral nerve Anatomy 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 230000007774 longterm Effects 0.000 description 8
- 206010019233 Headaches Diseases 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 208000019695 Migraine disease Diseases 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 206010015037 epilepsy Diseases 0.000 description 7
- 231100000869 headache Toxicity 0.000 description 7
- 238000012423 maintenance Methods 0.000 description 7
- 206010027599 migraine Diseases 0.000 description 7
- 238000007493 shaping process Methods 0.000 description 7
- 230000008093 supporting effect Effects 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 210000003371 toe Anatomy 0.000 description 7
- 230000001515 vagal effect Effects 0.000 description 7
- 208000023610 Pelvic Floor disease Diseases 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 6
- 238000002648 combination therapy Methods 0.000 description 6
- 210000004392 genitalia Anatomy 0.000 description 6
- 238000003306 harvesting Methods 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 239000012811 non-conductive material Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 208000027765 speech disease Diseases 0.000 description 6
- 206010069632 Bladder dysfunction Diseases 0.000 description 5
- 238000003491 array Methods 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000000653 nervous system Anatomy 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 230000006461 physiological response Effects 0.000 description 5
- 230000007115 recruitment Effects 0.000 description 5
- 210000005070 sphincter Anatomy 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 4
- 206010046543 Urinary incontinence Diseases 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 210000000467 autonomic pathway Anatomy 0.000 description 4
- 210000003050 axon Anatomy 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 208000029162 bladder disease Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 229940089093 botox Drugs 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 4
- 210000005230 lumbar spinal cord Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000008035 nerve activity Effects 0.000 description 4
- 208000001797 obstructive sleep apnea Diseases 0.000 description 4
- 210000003903 pelvic floor Anatomy 0.000 description 4
- 230000000737 periodic effect Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 102000005162 pleiotrophin Human genes 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 239000011253 protective coating Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000000392 somatic effect Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 230000007384 vagal nerve stimulation Effects 0.000 description 4
- 206010056948 Automatic bladder Diseases 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 3
- 206010027566 Micturition urgency Diseases 0.000 description 3
- 239000004642 Polyimide Substances 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 210000003484 anatomy Anatomy 0.000 description 3
- 210000003403 autonomic nervous system Anatomy 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 210000003792 cranial nerve Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000001255 hallux Anatomy 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 210000000118 neural pathway Anatomy 0.000 description 3
- 230000010004 neural pathway Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229920001721 polyimide Polymers 0.000 description 3
- 230000009158 reflex pathway Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 210000003497 sciatic nerve Anatomy 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 210000001590 sural nerve Anatomy 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 230000002889 sympathetic effect Effects 0.000 description 3
- 230000004797 therapeutic response Effects 0.000 description 3
- 238000011491 transcranial magnetic stimulation Methods 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 210000003708 urethra Anatomy 0.000 description 3
- 230000001720 vestibular Effects 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010011953 Decreased activity Diseases 0.000 description 2
- 206010052804 Drug tolerance Diseases 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 101150096243 FENS gene Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 229920000106 Liquid crystal polymer Polymers 0.000 description 2
- 239000004977 Liquid-crystal polymers (LCPs) Substances 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010036018 Pollakiuria Diseases 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 2
- 210000000579 abdominal fat Anatomy 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 238000011374 additional therapy Methods 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 230000002567 autonomic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 230000009172 bursting Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000001427 coherent effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000005574 cross-species transmission Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000009093 first-line therapy Methods 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 230000026781 habituation Effects 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000000642 iatrogenic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000011810 insulating material Substances 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 238000009115 maintenance therapy Methods 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920001643 poly(ether ketone) Polymers 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- -1 polytetrafluoroethylene Polymers 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229920002379 silicone rubber Polymers 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 229920006344 thermoplastic copolyester Polymers 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- ZNOCGWVLWPVKAO-UHFFFAOYSA-N trimethoxy(phenyl)silane Chemical compound CO[Si](OC)(OC)C1=CC=CC=C1 ZNOCGWVLWPVKAO-UHFFFAOYSA-N 0.000 description 2
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 2
- 208000022934 urinary frequency Diseases 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 230000036318 urination frequency Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- VRBFTYUMFJWSJY-UHFFFAOYSA-N 28804-46-8 Chemical compound ClC1CC(C=C2)=CC=C2C(Cl)CC2=CC=C1C=C2 VRBFTYUMFJWSJY-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000036829 Device dislocation Diseases 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000445129 Eremomyces bilateralis Species 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 229910002601 GaN Inorganic materials 0.000 description 1
- JMASRVWKEDWRBT-UHFFFAOYSA-N Gallium nitride Chemical compound [Ga]#N JMASRVWKEDWRBT-UHFFFAOYSA-N 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000489861 Maximus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010029174 Nerve compression Diseases 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- 208000009546 Neurogenic bowel Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 206010040744 Sinus headache Diseases 0.000 description 1
- 206010040840 Skin erosion Diseases 0.000 description 1
- 208000014604 Specific Language disease Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- NRTOMJZYCJJWKI-UHFFFAOYSA-N Titanium nitride Chemical compound [Ti]#N NRTOMJZYCJJWKI-UHFFFAOYSA-N 0.000 description 1
- 101150049278 US20 gene Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 230000009118 appropriate response Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000035581 baroreflex Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000003364 biologic glue Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000037410 cognitive enhancement Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 210000001619 diaphragma pelvis Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- HTXDPTMKBJXEOW-UHFFFAOYSA-N dioxoiridium Chemical compound O=[Ir]=O HTXDPTMKBJXEOW-UHFFFAOYSA-N 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000005071 external anal sphincter Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000002990 hypoglossal effect Effects 0.000 description 1
- 210000001169 hypoglossal nerve Anatomy 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910000457 iridium oxide Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000012804 iterative process Methods 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000025350 membrane depolarization involved in regulation of action potential Effects 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003666 myelinated nerve fiber Anatomy 0.000 description 1
- 238000001320 near-infrared absorption spectroscopy Methods 0.000 description 1
- 230000007433 nerve pathway Effects 0.000 description 1
- 230000008904 neural response Effects 0.000 description 1
- 210000004977 neurovascular bundle Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000008050 pain signaling Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- HWLDNSXPUQTBOD-UHFFFAOYSA-N platinum-iridium alloy Chemical compound [Ir].[Pt] HWLDNSXPUQTBOD-UHFFFAOYSA-N 0.000 description 1
- 229920003223 poly(pyromellitimide-1,4-diphenyl ether) Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000010344 pupil dilation Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000002416 recurrent laryngeal nerve Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 230000031893 sensory processing Effects 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000005641 tunneling Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 208000026533 urinary bladder disease Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003202 urodynamic effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36007—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of urogenital or gastrointestinal organs, e.g. for incontinence control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0456—Specially adapted for transcutaneous electrical nerve stimulation [TENS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/3603—Control systems
- A61N1/36034—Control systems specified by the stimulation parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36107—Sexual dysfunction
Landscapes
- Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Electrotherapy Devices (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3114528A CA3114528A1 (fr) | 2015-05-21 | 2016-05-20 | Systemes et methodes pour le traitement du dysfonctionnement urinaire |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62/165,037 | 2015-05-21 | ||
| US62/171,549 | 2015-06-05 | ||
| CA3114528A CA3114528A1 (fr) | 2015-05-21 | 2016-05-20 | Systemes et methodes pour le traitement du dysfonctionnement urinaire |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2986467A Division CA2986467C (fr) | 2015-05-21 | 2016-05-20 | Systemes et procedes de traitement du dysfonctionnement urinaire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3114528A1 true CA3114528A1 (fr) | 2022-10-09 |
Family
ID=83505486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3114528A Abandoned CA3114528A1 (fr) | 2015-05-21 | 2016-05-20 | Systemes et methodes pour le traitement du dysfonctionnement urinaire |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA3114528A1 (fr) |
-
2016
- 2016-05-20 CA CA3114528A patent/CA3114528A1/fr not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11752334B2 (en) | Method for treating a patient having a pelvic floor dysfunction | |
| US11529513B2 (en) | Neuromodulation system | |
| CA2931799C (fr) | Systemes et procedes pour ameliorer l'activation electrique d'un tissu nerveux | |
| US12115372B2 (en) | Monitoring and regulating physiological states and functions via sensory neural inputs to the spinal cord | |
| US20230381504A1 (en) | Treatment of incontinence by targeted nerve stimulation | |
| US11633593B2 (en) | Treatment of pelvic floor disorders using targeted lower limb nerve stimulation | |
| US11998738B2 (en) | Neuromodulation system | |
| US20240293671A1 (en) | Treatment of overactive bladder with phase-contingent pudendal nerve stimulation | |
| US20230256244A1 (en) | Treatment of pelvic floor disorders using targeted lower limb nerve stimulation | |
| CA3114528A1 (fr) | Systemes et methodes pour le traitement du dysfonctionnement urinaire |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20231121 |